Clinical Trials | Head & Neck Oncology Clinical & Health Services Research Group
Ground-Breaking Clinical Trials
The University of Michigan Head and Neck Oncology Program leads and participates in ground-breaking research and clinical trials. For more information on a particular trial, contact [email protected].
To learn more about The University of Michigan Head and Neck Oncology Clinical Trials, please view the Rogel Cancer Center Clinical Trials page Trial Search | Clinical Trial Information Hub.
BRIGHT
A Multi-Site, Parallel-Group, Randomized Clinical Trial Comparing a Brief Tele-Cognitive Behavioral Therapy Intervention (BRIGHT) with Attention Control for the Reduction of Body Image-Related Distress Among Head and Neck Cancer Survivors
Michigan Site-PI: Dr. David Forner, University of Michigan
Principal Investigator: Dr. Evan Graboyes, Medical University of South Carolina
Eligibility: Patients with head and neck cancer, within 1 year of cancer surgery
NRG HN14
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer (NRG HN14)
Michigan Site-PI: Dr. Keith Casper, University of Michigan
Principal Investigator: Dr. Neil Gross, MD Anderson
Eligibility: Patients with advanced squamous cell carcinoma of the skin
NRG HN006
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer (NRG HN006)
Michigan Site-PI: Dr. Marisa Buchakjian, University of Michigan
Principal Investigator: Dr. Stephen Lai, MD Anderson
Eligibility: Patients with early-stage oral cavity cancer
SELECT
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer (SELECT)
Michigan Site-PI: Dr. David Forner, University of Michigan
Principal Investigator: Dr. John de Almeida, University of Toronto
Eligibility: Patients with oropharyngeal (tonsil and base of tongue) cancer
NRG-HN015
A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patient with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)
Michigan Site-PI: Dr. Paul Swiecicki, University of Michigan
Principal Investigator: Dr. Nabil Saba, Emory University
Eligibility: Patients with head and neck cancer undergoing salvage surgery
PRECEDENT
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, (PRECEDENT)
Principal Investigator: Dr. Jennifer Shah, University of Michigan
Eligibility: Patients with oral cavity cancer
CuSToMIze
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of Michigan (CuSToMIze)
Principal Investigator: Dr. Michelle Mierzwa, University of Michigan
Eligibility: Patients with oropharyngeal (tonsil and base of tongue) cancer
SENIOR
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer (SENIOR-HN)
Principal Investigator: Dr. Paul Swiecicki, University of Michigan
Eligibility: Patients with head and neck cancer that would be treated with surgery
SN2426
A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
Principal Investigator: Dr. Paul Swiecicki, University of Michigan
Eligibility: Patients with recurrent inoperable or metastatic cutaneous squamous cell carcinoma
HEADWAY: Real-World Multicenter Quality Improvement Analysis of Neoadjuvant Immunotherapy in Head and Neck Squamous Cell Carcinoma
Multicenter, pragmatic 14-site investigation of incorporation of neoadjuvant immunotherapy into management of head and neck cancer.
Principal Investigator: Pratyusha Yalamanchi, MD MBA
Eligibility: Patients with biopsy-confirmed locally advanced head and neck squamous cell carcinoma
